These findings suggest a novel drug for the prevention of HT during thrombolysis in acute ischemic stroke through suppressing the LRP‐1, MMP2, and MMP9, which may pave the way for the development of preventive treatment with tPA thrombolysis after stroke in the pursuit of extending safety for the patient suffering an acute ischemic stroke. This evidence concerns the gene LRP1 and stroke disorder.